LINE

Text:AAAPrint
Photo

China approves inactivated COVID-19 vaccines for clinical trials(1/4)

2020-04-14 11:03:37 Xinhua Editor :Li Yan
1

Staff members talk beside the virus culture/inactivation area of a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020. China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday. The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical trials of the two vaccines have started. (Xinhua/Zhang Yuwei)

China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday.

The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical trials of the two vaccines have started.

A staff member tests samples of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 11, 2020. China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday. The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical trials of the two vaccines have started. (Xinhua/Zhang Yuwei)

A staff member displays a sample of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020. China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday. The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical trials of the two vaccines have started. (Xinhua/Zhang Yuwei)

Samples of the COVID-19 inactivated vaccine are seen at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020. China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday. The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical trials of the two vaccines have started. (Xinhua/Zhang Yuwei)

LINE
    ${visuals_2}
    ${visuals_3}
    ${new_video_hd2}
    ${new_video_hd3}
LINE
Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2020 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
第九色区AV天堂 亚洲2017无码中文字幕 日本高清视频免费版毛片 男人在天堂a视频 <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>